OwnershipPrivately heldSEC Form D filed 2026-07-15; no listing for this SEC registrant in the SEC tickers file · checked Oct 28, 2026
Commercial developmentNot yet assessedWe only state a stage once a source supports it. Having a product on sale does not show it works or makes money.
Investment accessNo accessible investment route verifiedPast private offerings were limited to eligible investors. They are records of earlier sales, not open offers. · checked Oct 28, 2026
Evidence is labelled on each development below (company-reported, regulatory filing or government record), not on the company as a whole. Coverage is not an offer to invest. Private ownership does not imply available shares. Next scheduled recheck: Nov 27, 2026.
1developments published
—US federal obligations on record
6private-offering notices since 2019
Jul 15, 2026latest development
Timeline
- Jul 15, 2026 · Private financing (Form D)
Cambrian Bio reports $123.8 million of equity sold in a private offering
Regulatory filing
Profile
- Legal name
- Cambrian BioPharma Inc
- SEC filer
- CIK 0001797409 ↗
- Incorporated
- DE
- Coverage
- Offering notices + any filings + federal awards
Mix of developments
Watch Cambrian Bio
Anything new from Cambrian Bio lands in your digest, with the source beside it. Following is about information, never an investment action. Up to 10 companies or frontiers on Pro, $49/month.
Follow this companyPreview a sample digestPrivate offerings reported to the SEC (Form D)
A Form D is a notice a company files after selling securities without a public registration. Amount sold is cumulative for that offering as reported by the company; an amendment (D/A) updates an earlier notice, so rows are not added together. None of these is a valuation or an open offer.
| Filed | Form | Amount sold | Offering size | First sale | Investors | Exemption | Record |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | D | $124 million | $130 million | Jun 30, 2026 | 80 | Rule 506(c) | SEC ↗ |
| Jan 13, 2025 | D/A | $23.0 million | $37.6 million | Jun 2, 2023 | 30 | Rule 506(b) | SEC ↗ |
| Dec 22, 2023 | D | $7.7 million | $40.0 million | Jun 2, 2023 | 20 | Rule 506(b) | SEC ↗ |
| Dec 2, 2021 | D | $92.2 million | $101 million | Oct 13, 2021 | 56 | Rule 506(b) | SEC ↗ |
| May 6, 2021 | D | $28.4 million | $28.4 million | Oct 20, 2020 | 30 | Rule 506(b) | SEC ↗ |
| Jan 27, 2020 | D | $4.8 million | $4.8 million | Oct 29, 2019 | 5 | Rule 506(b) | SEC ↗ |